| 產(chǎn)品名稱 |
Vaccinia virus |
| 商品貨號 |
B210515 |
| Classification |
Poxviridae, Orthopoxvirus |
| Agent |
Vaccinia virus |
| Strain |
CL |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen 1 mL per vial |
| Storage Conditions |
?-70°C or colder |
| Comments |
VR-1774 is produced in BSC-40 cells, which is a change in cell line from ATCC VR-117 to increase titer. |
| Effect on Host |
?CPE, refractile cell rounding CPE, refractile cell rounding |
| Recommended Host |
Production Host: ?BSC-40 (ATCC? CRL-2761™) BSC-40 (ATCC CRL-2761) |
| Growth Conditions |
Temperature: 37°C Growth Conditions: Plate cells 24-48 hours in advance and infect when cultures are 90 to 95% confluent. Remove medium and inoculate with a small volume (e.g. 1 mL per 25 cm2) of virus diluted to provide an optimal MOI (e.g. 0.1). Adsorb 30 minutes at 37°C in a humidified 5% CO2 atmosphere, rocking every 7-10 minutes to redistribute inoculum. End adsorption by adding virus growth medium. Incubation: 1-3 days |
| Name of Depositor |
F Fenner, Australian National University |
| Source |
Most likely derived from New York City Department of Health strain of vaccinia virus. Cell culture adapted to BSC-40 cells. |
| References |
Fenner, F and Burnet, FM. A short description of the Poxvirus group (Vaccinia and related viruses). Virology 4: 305-314, 1957. PubMed: 13496547.
Craigie J. . Br. J. Exp. Pathol. 13: 259, 1932.
Parker RF, et al. Further studies of the infectious unit of Vaccinia. J. Exp. Med. 74: 263-281, 1941.
|
